

Ali Badiie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7944802/publications.pdf>

Version: 2024-02-01

96
papers

2,565
citations

159585

30
h-index

223800

46
g-index

99
all docs

99
docs citations

99
times ranked

3065
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin. <i>Journal of Controlled Release</i> , 2015, 220, 275-286.	9.9	152
2	Crystal Habit Modifications of Ibuprofen and Their Physicomechanical Characteristics. <i>Drug Development and Industrial Pharmacy</i> , 2001, 27, 803-809.	2.0	105
3	Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. <i>International Journal of Pharmaceutics</i> , 2013, 458, 324-333.	5.2	90
4	The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of <i>Leishmania</i> (rgp63) encapsulated in cationic liposome. <i>Vaccine</i> , 2007, 25, 6107-6117.	3.8	82
5	The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen. <i>Experimental Parasitology</i> , 2012, 132, 403-409.	1.2	74
6	Micro/nanoparticle adjuvants for antileishmanial vaccines: Present and future trends. <i>Vaccine</i> , 2013, 31, 735-749.	3.8	70
7	Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region. <i>Journal of Controlled Release</i> , 2015, 220, 308-315.	9.9	69
8	Redox-sensitive nanoscale drug delivery systems for cancer treatment. <i>International Journal of Pharmaceutics</i> , 2020, 589, 119882.	5.2	65
9	Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 139, 228-236.	5.0	62
10	<i>Leishmania major</i> : Immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. <i>Experimental Parasitology</i> , 2007, 115, 127-134.	1.2	59
11	P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. <i>Cancer Letters</i> , 2014, 355, 54-60.	7.2	58
12	Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN. <i>Immunology Letters</i> , 2014, 162, 87-93.	2.5	58
13	MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. <i>Journal of Controlled Release</i> , 2019, 303, 223-236.	9.9	58
14	The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of <i>Leishmania</i> (rgp63). <i>Experimental Parasitology</i> , 2009, 121, 362-369.	1.2	50
15	Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system. <i>Atherosclerosis</i> , 2019, 283, 69-78.	0.8	49
16	Preparation, characterization and in vivo evaluation of alginate-coated chitosan and trimethylchitosan nanoparticles loaded with PR8 influenza virus for nasal immunization. <i>Asian Journal of Pharmaceutical Sciences</i> , 2019, 14, 216-221.	9.1	46
17	Preparation and characterization of stable nanoliposomal formulations of curcumin with high loading efficacy: In vitro and in vivo anti-tumor study. <i>International Journal of Pharmaceutics</i> , 2020, 580, 119211.	5.2	46
18	Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis. <i>Vaccine</i> , 2012, 30, 3957-3964.	3.8	45

#	ARTICLE	IF	CITATIONS
19	Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA). <i>Acta Tropica</i> , 2013, 128, 528-535.	2.0	45
20	Coencapsulation of CpG Oligodeoxynucleotides with Recombinant Leishmania major Stress-Inducible Protein 1 in Liposome Enhances Immune Response and Protection against Leishmaniasis in Immunized BALB/c Mice. <i>Vaccine Journal</i> , 2008, 15, 668-674.	3.1	44
21	Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. <i>Vaccine</i> , 2007, 25, 4757-4766.	3.8	43
22	Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model. <i>International Journal of Pharmaceutics</i> , 2015, 495, 162-170.	5.2	43
23	Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 325-336.	5.0	41
24	Liposomal CpG-ODN: An in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 119, 159-170.	4.0	40
25	A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice. <i>Journal of Drug Targeting</i> , 2018, 26, 365-372.	4.4	40
26	Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice. <i>Acta Tropica</i> , 2019, 196, 142-149.	2.0	35
27	The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma. <i>International Journal of Pharmaceutics</i> , 2014, 473, 326-333.	5.2	34
28	Therapeutic Efficacy of Cisplatin Thermosensitive Liposomes upon Mild Hyperthermia in C26 Tumor Bearing BALB/c Mice. <i>Molecular Pharmaceutics</i> , 2017, 14, 712-721.	4.6	33
29	Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis. <i>Parasitology Research</i> , 2012, 111, 105-114.	1.6	32
30	Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors. <i>International Journal of Pharmaceutics</i> , 2016, 505, 89-95.	5.2	31
31	Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model. <i>Immunology Letters</i> , 2016, 176, 57-64.	2.5	31
32	Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response. <i>Immunologic Research</i> , 2018, 66, 200-206.	2.9	30
33	Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): The role of bilayer composition. <i>Colloids and Surfaces B: Biointerfaces</i> , 2009, 74, 37-44.	5.0	29
34	Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer. <i>Immunology Letters</i> , 2017, 190, 108-117.	2.5	29
35	P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 664-672.	2.8	29
36	Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis. <i>Experimental Parasitology</i> , 2014, 146, 78-86.	1.2	27

#	ARTICLE	IF	CITATIONS
37	Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity. <i>International Journal of Pharmaceutics</i> , 2016, 511, 236-244.	5.2	26
38	Immunogenicity and antitumor activity of the superlytic λ F7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice. <i>Cancer Letters</i> , 2018, 424, 109-116.	7.2	25
39	Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide. <i>Journal of Drug Targeting</i> , 2021, 29, 617-630.	4.4	25
40	PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells. <i>Nanomedicine</i> , 2017, 12, 1475-1490.	3.3	24
41	Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16FO melanoma. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 80, 66-73.	4.0	23
42	Optimization of a Method to Prepare Liposomes Containing HER2/Neu- Derived Peptide as a Vaccine Delivery System for Breast Cancer. <i>Iranian Journal of Pharmaceutical Research</i> , 2014, 13, 15-25.	0.5	23
43	Liposomal adjuvant development for leishmaniasis vaccines. <i>Therapeutic Advances in Vaccines</i> , 2017, 5, 85-101.	2.7	21
44	Cell cytotoxicity, immunostimulatory and antitumor effects of lipid content of liposomal delivery platforms in cancer immunotherapies. A comprehensive in-vivo and in-vitro study. <i>International Journal of Pharmaceutics</i> , 2019, 567, 118492.	5.2	21
45	Preparation of liposomes containing IFN-gamma and their potentials in cancer immunotherapy: In vitro and in vivo studies in a colon cancer mouse model. <i>Life Sciences</i> , 2021, 264, 118605.	4.3	19
46	Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy. <i>Scientific Reports</i> , 2021, 11, 14661.	3.3	19
47	Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. <i>Iranian Journal of Basic Medical Sciences</i> , 2015, 18, 385-92.	1.0	19
48	The role of liposome-protamine-DNA nanoparticles containing CpG oligodeoxynucleotides in the course of infection induced by <i>Leishmania major</i> in BALB/c mice. <i>Experimental Parasitology</i> , 2012, 132, 313-319.	1.2	18
49	Enhancement of the effect of BCG vaccine against tuberculosis using DDA/TDB liposomes containing a fusion protein of HspX, PPE44, and EsxV. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 370-377.	2.8	18
50	Liposomal nanocarriers for statins: A pharmacokinetic and pharmacodynamics appraisal. <i>Journal of Cellular Physiology</i> , 2019, 234, 1219-1229.	4.1	18
51	Preparation, characterization and improved release profile of ibuprofen-phospholipid association. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 60, 101951.	3.0	18
52	Cationic liposomes formulated with a novel whole <i>Leishmania</i> lysate (WLL) as a vaccine for leishmaniasis in murine model. <i>Immunobiology</i> , 2018, 223, 493-500.	1.9	17
53	Coadministration of <i>L. major</i> amastigote class I nuclease (rLmaCIN) with LPD nanoparticles delays the progression of skin lesion and the <i>L. major</i> dissemination to the spleen in BALB/c mice-based experimental setting. <i>Acta Tropica</i> , 2016, 159, 211-218.	2.0	15
54	Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma. <i>Vaccine</i> , 2020, 38, 5665-5677.	3.8	15

#	ARTICLE	IF	CITATIONS
55	Development of RNA aptamers as molecular probes for HER2(+) breast cancer study using cell-SELEX. Iranian Journal of Basic Medical Sciences, 2015, 18, 576-86.	1.0	15
56	Development of nano-carriers for <i>Leishmania</i> vaccine delivery. Expert Opinion on Drug Delivery, 2020, 17, 167-187.	5.0	14
57	Preparation of nanoliposomes linked to HER2/neu-derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer. Journal of Cellular Biochemistry, 2019, 120, 1294-1303.	2.6	13
58	Redox-sensitive doxorubicin liposome: a formulation approach for targeted tumor therapy. Scientific Reports, 2022, 12, .	3.3	13
59	<i>Ex vivo</i> -generated dendritic cell-based vaccines in melanoma: the role of nanoparticulate delivery systems. Immunotherapy, 2020, 12, 333-349.	2.0	12
60	pH-Sensitive PEGylated Liposomal Silybin: Synthesis, In Vitro and In Vivo Anti-Tumor Evaluation. Journal of Pharmaceutical Sciences, 2021, 110, 3919-3928.	3.3	11
61	Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids. Current Drug Delivery, 2017, 14, 492-502.	1.6	11
62	Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer. PLoS ONE, 2020, 15, e0243550.	2.5	11
63	Nanocarriers Call the Last Shot in the Treatment of Brain Cancers. Technology in Cancer Research and Treatment, 2022, 21, 153303382210809.	1.9	11
64	The role of LPD-nanoparticles containing recombinant major surface glycoprotein of <i>Leishmania</i> (rgp63) in protection against leishmaniasis in murine model. Immunopharmacology and Immunotoxicology, 2018, 40, 72-82.	2.4	10
65	A simple and effective approach for the treatment of dyslipidemia using anionic nanoliposomes. Colloids and Surfaces B: Biointerfaces, 2014, 122, 645-652.	5.0	9
66	Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice. Iranian Journal of Basic Medical Sciences, 2013, 16, 965-72.	1.0	9
67	Recent advancements in nanoparticle-mediated approaches for restoration of multiple sclerosis. Journal of Controlled Release, 2022, 343, 620-644.	9.9	9
68	Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia. Colloids and Surfaces B: Biointerfaces, 2015, 129, 71-78.	5.0	8
69	The impact of nanocarriers in the induction of antigen-specific immunotolerance in autoimmune diseases. Journal of Controlled Release, 2021, 339, 274-283.	9.9	8
70	The Role of Liposomal CpG ODN on the Course of L. major Infection in BALB/C Mice. Iranian Journal of Parasitology, 2010, 5, 47-54.	0.6	8
71	Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model. Iranian Journal of Basic Medical Sciences, 2012, 15, 1032-45.	1.0	8
72	miR-155 influences cell-mediated immunity in Balb/c mice treated with aflatoxin M ₁ . Drug and Chemical Toxicology, 2021, 44, 39-46.	2.3	7

#	ARTICLE	IF	CITATIONS
73	Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy. Iranian Journal of Basic Medical Sciences, 2020, 23, 1065-1077.	1.0	7
74	<sc>PEG</sc>ylation of cationic liposomes encapsulating soluble <i>Leishmania</i> antigens reduces the adjuvant efficacy of liposomes in murine model. Parasite Immunology, 2017, 39, e12492.	1.5	6
75	Development and characterization of a multiparticulate drug delivery system containing indomethacin-phospholipid complex to improve dissolution rate. Journal of Drug Delivery Science and Technology, 2019, 53, 101177.	3.0	6
76	AE36 HER2/neu-derived peptide linked to positively charged liposomes with CpG-ODN as an effective therapeutic and prophylactic vaccine for breast cancer. Journal of Drug Delivery Science and Technology, 2022, 67, 102904.	3.0	6
77	Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects. Iranian Journal of Basic Medical Sciences, 2015, 18, 506-13.	1.0	6
78	The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice. Iranian Journal of Basic Medical Sciences, 2016, 19, 178-86.	1.0	6
79	Anti-atherosclerosis effect of different doses of CETP vaccine in rabbit model of atherosclerosis. Biomedicine and Pharmacotherapy, 2016, 81, 468-473.	5.6	5
80	A validated 1H-NMR method for quantitative analysis of DOTAP lipid in nanoliposomes containing soluble Leishmania antigen. Journal of Pharmaceutical and Biomedical Analysis, 2021, 194, 113809.	2.8	5
81	Increasing Cellular Immune Response in Liposomal Formulations of DOTAP Encapsulated by Fusion Protein Hsp α , PPE44, And Esxv, as a Potential Tuberculosis Vaccine Candidate. Reports of Biochemistry and Molecular Biology, 2019, 7, 156-166.	1.4	5
82	Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model. International Immunopharmacology, 2021, 98, 107833.	3.8	4
83	Development of a novel formulation method to prepare liposomal Epcadostat. European Journal of Pharmaceutical Sciences, 2021, 165, 105954.	4.0	4
84	Development of a stable and high loaded liposomal formulation of lapatinib with enhanced therapeutic effects for breast cancer in combination with Caelyx $\text{\textcircled{R}}$: In vitro and in vivo evaluations. Colloids and Surfaces B: Biointerfaces, 2021, 207, 112012.	5.0	4
85	An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis. Expert Opinion on Drug Delivery, 2021, 18, 1795-1813.	5.0	4
86	Immunization against PR8 influenza virus with chitosan-coated ISCOMATRIX nanoparticles. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 587-593.	2.8	3
87	Development of an effective liposomal cholesterol ester transfer protein (CETP) vaccine for protecting against atherosclerosis in rabbit model. Pharmaceutical Development and Technology, 2020, 25, 432-439.	2.4	3
88	Efficacy Comparison of TAT Peptide-Functionalized PEGylated Liposomal Doxorubicin in C26 and B16F0 Tumor Mice Models. International Journal of Peptide Research and Therapeutics, 2021, 27, 2099-2109.	1.9	3
89	The role of nanoliposome bilayer composition containing soluble antigen on maturation and activation of dendritic cells. Iranian Journal of Basic Medical Sciences, 2018, 21, 536-545.	1.0	3
90	A Phospholipase-A Activity in Soluble Leishmania Antigens Causes Instability of Liposomes. Current Drug Delivery, 2020, 17, 806-814.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Evaluation of Immune Response against Leishmaniasis in BALB/c Mice Immunized with Cationic DOTAP/DOPE/CHOL Liposomes Containing Soluble Antigens. Iranian Journal of Parasitology, 2019, 14, 68-77.	0.6	2
92	Evaluation of Immune Response against Leishmaniasis in BALB/c Mice Immunized with Cationic DOTAP/DOPE/CHOL Liposomes Containing Soluble Leishmania major Antigens. Iranian Journal of Parasitology, 0, , .	0.6	1
93	Multi-antigen vaccination with LPD nanoparticles containing rgp63 and rLmaC1N proteins induced effective immune response against leishmaniasis in animal model. Journal of Drug Delivery Science and Technology, 2021, 64, 102633.	3.0	0
94	A novel atheroprotective role of MF59-like adjuvant when co-administered with CETP vaccine in rabbit model of atherosclerosis. Iranian Journal of Basic Medical Sciences, 2016, 19, 1345-1352.	1.0	0
95	A novel formulation of Mtb72F DNA vaccine for immunization against tuberculosis. Iranian Journal of Basic Medical Sciences, 2020, 23, 826-832.	1.0	0
96	Sphingomyelin liposome bearing whole lysate antigens induce strong Th2 immune response in BALB/c mice. Iranian Journal of Basic Medical Sciences, 2021, 24, 222-231.	1.0	0